NCT03157167 2025-03-05
An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
Navidea Biopharmaceuticals
Phase 1 Completed
Clinical Trials
8 trialsNCT02509598 2024-06-28
A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Cardinal Health 414, LLC
Phase 2 Completed
NCT03029988 2020-09-10
An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.
Navidea Biopharmaceuticals
Phase 1 Terminated
NCT02509585 2019-02-11
A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection
Cardinal Health 414, LLC
Phase 2 Terminated
NCT02201420 2016-09-27
Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT
Navidea Biopharmaceuticals
Phase 2 Completed
NCT00911326 2014-08-08
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
Navidea Biopharmaceuticals
Phase 3 Terminated
NCT00671918 2013-06-17
Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
Navidea Biopharmaceuticals
Phase 3 Completed
NCT01106040 2013-06-17
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Navidea Biopharmaceuticals
Phase 3 Completed